A 6-week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 Administered With Canagliflozin In Adult Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2014
At a glance
- Drugs PF 5175157 (Primary) ; Canagliflozin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 16 May 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 28 Apr 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.